Johnson & Johnson (NYSE:JNJ) Shares Sold by Rational Advisors LLC

Rational Advisors LLC cut its stake in Johnson & Johnson (NYSE:JNJ) by 39.2% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,022 shares of the company’s stock after selling 1,305 shares during the period. Rational Advisors LLC’s holdings in Johnson & Johnson were worth $328,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. China Universal Asset Management Co. Ltd. bought a new stake in Johnson & Johnson during the first quarter valued at $765,000. Shariaportfolio Inc. increased its stake in Johnson & Johnson by 2.3% during the first quarter. Shariaportfolio Inc. now owns 14,655 shares of the company’s stock valued at $2,318,000 after purchasing an additional 325 shares during the last quarter. Prosperity Consulting Group LLC increased its stake in Johnson & Johnson by 9.3% during the first quarter. Prosperity Consulting Group LLC now owns 11,255 shares of the company’s stock valued at $1,780,000 after purchasing an additional 957 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. increased its stake in Johnson & Johnson by 11.0% during the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 563,628 shares of the company’s stock valued at $86,265,000 after purchasing an additional 55,653 shares during the last quarter. Finally, Centric Wealth Management grew its position in shares of Johnson & Johnson by 25.3% during the first quarter. Centric Wealth Management now owns 3,592 shares of the company’s stock worth $519,000 after acquiring an additional 725 shares during the last quarter. 69.55% of the stock is owned by institutional investors and hedge funds.

Johnson & Johnson Price Performance

Shares of NYSE JNJ opened at $158.24 on Tuesday. Johnson & Johnson has a twelve month low of $143.13 and a twelve month high of $168.85. The company has a current ratio of 1.03, a quick ratio of 0.79 and a debt-to-equity ratio of 0.45. The company has a market capitalization of $380.98 billion, a price-to-earnings ratio of 22.90, a PEG ratio of 2.84 and a beta of 0.53. The firm has a 50-day moving average of $163.18 and a two-hundred day moving average of $155.68.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Tuesday, October 15th. The company reported $2.42 earnings per share for the quarter, beating analysts’ consensus estimates of $2.21 by $0.21. Johnson & Johnson had a net margin of 19.14% and a return on equity of 35.45%. The company had revenue of $22.47 billion during the quarter, compared to the consensus estimate of $22.17 billion. During the same period in the prior year, the company earned $2.66 EPS. Johnson & Johnson’s revenue was up 5.2% on a year-over-year basis. As a group, analysts expect that Johnson & Johnson will post 9.94 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 10th. Shareholders of record on Tuesday, November 26th will be paid a dividend of $1.24 per share. This represents a $4.96 dividend on an annualized basis and a yield of 3.13%. The ex-dividend date is Tuesday, November 26th. Johnson & Johnson’s dividend payout ratio is presently 71.78%.

Insider Buying and Selling at Johnson & Johnson

In other Johnson & Johnson news, VP Robert J. Decker sold 5,635 shares of the company’s stock in a transaction dated Friday, August 30th. The shares were sold at an average price of $165.06, for a total transaction of $930,113.10. Following the completion of the sale, the vice president now directly owns 18,973 shares of the company’s stock, valued at approximately $3,131,683.38. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 0.16% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on the stock. Citigroup upped their price target on shares of Johnson & Johnson from $180.00 to $185.00 and gave the stock a “buy” rating in a research report on Wednesday, October 16th. Cantor Fitzgerald restated an “overweight” rating and set a $215.00 price target on shares of Johnson & Johnson in a research report on Wednesday, October 16th. TD Securities lowered their price target on shares of Johnson & Johnson from $195.00 to $185.00 in a research report on Thursday, July 18th. TD Cowen lowered their price target on shares of Johnson & Johnson from $195.00 to $185.00 and set a “buy” rating for the company in a research report on Thursday, July 18th. Finally, Wells Fargo & Company upped their price target on shares of Johnson & Johnson from $163.00 to $166.00 and gave the stock an “equal weight” rating in a research report on Wednesday, October 16th. Six research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $175.93.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.